The Development of Preliminary HiTOP Internalizing Spectrum Scales

Watson, David; Forbes, Miriam K.; Levin‐Aspenson, Holly F.; Ruggero, Camilo J.; Kotelnikova, Yuliya; Khoo, Shereen; Bagby, R. Michael; Sunderland, Matthew; Patalay, Praveetha; Kotov, Roman

doi:10.1177/10731911211003976

Cited by 34 publications

(40 citation statements)

References 45 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As has historically been the case, new nosological proposals are often followed by an attempt to assess psychopathology in a manner that conforms to the new perspective. Thus, it no surprise that members of the HiTOP consortium has formed working groups aimed at measuring psychopathology that is in line with their dimensional model (Cicero et al, 2021;Sellbom et al, in press;Simms et al, in press;Watson et al, 2021;Zimmerman et al, in press).…”

mentioning

confidence: 99%

Measurement to Improve Treatment Delivery: A Commentary on the HiTOP Measure Development Project

Sauer‐Zavala

2021

Assessment

View full text Add to dashboard Cite

The focus on this commentary will be on how dimensional models of psychopathology, particularly HiTOP model, have the potential to significantly streamline treatment efforts and increase the likelihood that evidence-based interventions are more widely integrated in clinical practice. The approach to assessment adopted by the HiTOP consortium is likely to have an outsized impact on whether these innovations are adopted in routine clinical practice. Toward that end, I provide suggestions for a measurement strategy that can maximize clinical utility. In particular, the tension between creating items that reflect all phenomena at the sign/symptom level to refine our understanding of relationships among psychopathological constructs and creating a measure that is suitable for clinical practice is explored.

show abstract

mentioning

confidence: 99%

Measurement to Improve Treatment Delivery: A Commentary on the HiTOP Measure Development Project

Sauer‐Zavala

2021

Assessment

View full text Add to dashboard Cite

show abstract

“…This article is intended solely for the personal use of the individual user and is not to be disseminated broadly. symptoms, as distress symptoms are particularly strongly associated with NA (Watson & Naragon-Gainey, 2014;Watson et al, 2022). Although we are not able to test this definitively without EMA measures specific to distress and fear, the PANAS previously has been used to create subscales as proxies for distress and fear (e.g., Ebesutani et al, 2011).…”

Section: Discussionmentioning

confidence: 91%

“…Well-Being as conceptualized in the IDAS has been described as capturing high energy and positive affectivity (Watson et al, 2007), such that it appears to be quite similar to PA. Regarding the Dysphoria scale, the very strong between-person correlation with NA may be driven by variance shared with distress (vs. fear) symptoms, as distress symptoms are particularly strongly associated with NA (Watson & Naragon-Gainey, 2014; Watson et al, 2022). Although we are not able to test this definitively without EMA measures specific to distress and fear, the PANAS previously has been used to create subscales as proxies for distress and fear (e.g., Ebesutani et al, 2011).…”

Section: Discussionmentioning

confidence: 99%

“…There are other empirically based measures of internalizing disorders that model symptoms dimensionally. For example, the preliminary HiTOP internalizing spectrum scales recently developed by Watson et al (2022) include 39 scales in total that capture fear, distress, mania, body dysmorphia, and sexual dysfunction. While this measure is specific to HiTOP, it is still preliminary, and will continue to undergo substantial changes as more data are collected for measurement of the HiTOP model more broadly.…”

Section: Structure and Content Of Internalizing Symptomsmentioning

confidence: 99%

See 1 more Smart Citation

Dysphoria and well-being in daily life: Development and validation of ecological momentary assessment scales.

Jimenez¹,

McMahon²,

Watson³

et al. 2022

Psychological Assessment

Self Cite

View full text Add to dashboard Cite

Assessment of internalizing symptoms has generally relied on cross-sectional and retrospective self-reports, but ecological momentary assessment (EMA) is increasingly used to capture quick fluctuations in symptoms, enhance ecological validity, and improve recall accuracy. However, there are very few measures of internalizing symptoms that have been validated for use in EMA designs. In Study 1, we chose candidate items for EMA short forms of the Dysphoria and Well-Being scales from the Inventory of Depression and Anxiety Symptoms (IDAS), based on principal factor analyses and internal consistency analyses conducted on aggregated cross-sectional datasets (total N = 8,876). In Study 2, we tested the items using an EMA design in a sample of college students (N = 279) oversampled for elevated neuroticism. Scale structure, reliability, and convergent and discriminant validity (regarding baseline IDAS scales, baseline affect, and EMA affect) were evaluated at the within-and between-person levels using multilevel structural equation modeling. Exploratory and confirmatory factor analyses in separate subsamples revealed the expected two-factor structure, yielding a four-item Well-Being scale and a five-item Dysphoria scale. Both scales showed acceptable to good internal consistency, strong convergent validity, and generally adequate discriminant validity. However, some associations of the new scales with EMA affect (i.e., Dysphoria with negative affect; Well-Being with positive affect) were very strong at the between-person level, such that they were not empirically distinct. Overall, this study provides an initial validation of brief EMA-IDAS Dysphoria and Well-Being scales that can be used in research or clinical settings, with particular utility for capturing within-person, dynamic effects. Public Significance StatementThe present study performed the first stages of creating a brief measure of depression and anxiety symptoms. Our results provide initial evidence that this measure is appropriate for use in repeated momentary assessments (e.g., research conducted via smartphone surveys that occur multiple times a day). Additionally, it highlights important considerations for measures used in repeated momentary assessments of psychological symptoms.

show abstract

“…Sleep. NIDA PhAB's Sleep dimension probably also overlaps with HiTOP's Internalizing spectrum given that some sleep problems (i.e., insomnia, lassitude, nightmares) are directly incorporated into the assessment of HiTOP Internalizing (Watson et al, 2021). Instead, both systems focus on the potential bidirectional associations between internalizing and sleep problems, such that stress, anxiety, and depression are thought to cause disruptions in sleep and poor sleep quality, which exacerbates anxiety and mood problems (Cox & Olatunji, 2020).…”

Section: Executive Function Most Directly We Propose a Link Between N...mentioning

confidence: 99%

New approaches to deep phenotyping in addictions

Watts¹,

Latzman²,

Boness³

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Objective: The causes of substance use disorders (SUDs) are largely unknown and the effectiveness of their treatments is limited. One crucial impediment to research and treatment progress surrounds how SUDs are classified and diagnosed. Given the substantial heterogeneity among individuals diagnosed with a given SUD (e.g., alcohol use disorder), identifying novel research and treatment targets and developing new study designs is daunting. Method: In this paper, we review and integrate two recently developed frameworks, the NIDA Phenotyping Assessment Battery (NIDA PhAB) and the Hierarchical Taxonomy of Psychopathology (HiTOP), that hope to accelerate progress in understanding the causes and consequences of psychopathology by means of deep phenotyping, or finer-grained analysis of phenotypes. Results and Conclusions: NIDA PhAB focuses on addiction-related processes across multiple units of analysis, whereas HiTOP focuses on clinical phenotypes and covers a broader range of psychopathology. We highlight that NIDA PhAB and HiTOP together provide deep and broad characterizations of people diagnosed with SUDs and complement each other in their efforts to address widely known limitations of traditional classification systems and their diagnostic categories. Next, we show how NIDA PhAB and HiTOP can be integrated to facilitate optimal rich phenotyping of addiction-related phenomena. Finally, we argue that such deep phenotyping promises to advance our understanding of the neurobiology of SUD and addiction, which will guide the development of personalized medicine and interventions.

show abstract

The Development of Preliminary HiTOP Internalizing Spectrum Scales

Cited by 34 publications

References 45 publications

Measurement to Improve Treatment Delivery: A Commentary on the HiTOP Measure Development Project

Measurement to Improve Treatment Delivery: A Commentary on the HiTOP Measure Development Project

Dysphoria and well-being in daily life: Development and validation of ecological momentary assessment scales.

New approaches to deep phenotyping in addictions

Contact Info

Product

Resources

About